Antibody therapy for COVID-19.

Lennart Hammarström, Harold Marcotte, Antonio Piralla, Fausto Baldanti, Qiang Pan-Hammarström

Journal: Current opinion in allergy and clinical immunology 2021;21(6):553-558

PMID: 34570010

Free Full Text on PubMed Central View on PubMed

Abstract

PURPOSE OF REVIEW

To provide an update of the current state of antibody therapy for Severe Acute Respiratory Syndrome Coronavirus 2 infection that has progressed immensely in a very short time period.

RECENT FINDINGS

Limited clinical effect of classical passive immunotherapy (plasma therapy, hyperimmune immunoglobulin [IgG] preparations) whereas monoclonal antibody therapy, if initiated early in the disease process, shows promising results.

SUMMARY

Although antibody therapy still remains to be fully explored in patients with COVID-19, a combination of IgG monoclonal antibodies against the receptor-binding domain of the spike protein currently appears to provide the best form of antibody therapy, Immunoglobulin A dimers and Immunoglobulin M pentamers also show promising preliminary therapeutic results.

Address: Department of Biosciences and Nutrition, NEO, Karolinska Institutet, Huddinge.; Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden.; Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo.; Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo.; Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.

DOI: 10.1097/ACI.0000000000000787

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/covid19coronavirusdisease2...

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-BRIP1-5

Subscription / membership required

Full Text Sources:

MeSH Terms: Antibodies, Monoclonal, COVID-19, Clinical Trials as Topic, Humans, Immunization, Passive, Immunoglobulin A, Immunoglobulin G, Immunoglobulin M, SARS-CoV-2, Treatment Outcome, COVID-19 Serotherapy